Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Personalized cardiac pacing; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 30
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 26 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 8
States / cities: Newport Beach, California • Tarzana, California • Middlebury, Connecticut + 5 more

Conditions: Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
Interventions: Thoracic Aortic Surgery; Procedure
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years to 79 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 16
States / cities: San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 12 more

Conditions: BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
Interventions: Ruxolitinib; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 4
States / cities: Palo Alto, California • Portland, Oregon • Salt Lake City, Utah + 1 more

Conditions: Obstructive Sleep Disorder, Obstructive Sleep Apnea, Tonsillar Hypertrophy
Interventions: Micropolysaccharide Hemospheres (Arista), Electrocautery (Monopolar suction cautery); Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 5 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions: Hyperpolarized 13C-Pyruvate; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: Eplerenone, Chlorthalidone, Potassium; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Heart Diseases, Atherosclerosis, HIV Infections, Cardiomyopathy, Hypertrophic
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: Up to 2 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 5
States / cities: Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Benign Prostatic Hypertrophy
Interventions: Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 46
States / cities: Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more

Conditions: Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Genetic Disease, Cardiology
Interventions: Large Language Model; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cardiomyopathy, Hypertrophic
Interventions: MYK-224; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Interventions: Ureteroscope system, Laser system; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Phoenix, Arizona • Miami, Florida • Tampa, Florida + 2 more

Conditions: Metastases
Interventions: Yttrium-90 (Y-90) resin microspheres; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastro-Intestinal Cancer
Interventions: 5-FU, Leucovorin, Irinotecan, Brivanib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Dallas, Texas • Temple, Texas

Conditions: Blood Flow Restriction and Low-Intensity Resistance Training
Interventions: Blood Flow Restriction Cuffs, Low-Intensity Resistance Training, High-Intensity Resistance Training; Device · Other
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years to 30 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Acute Decompensated Heart Failure, Heart Failure
Interventions: Not listed
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hypertrophic Cardiomyopathy, Long QT Syndrome
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 60 Years
Enrollment: 4,299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 29
States / cities: Tucson, Arizona • Orange, California • San Diego, California + 24 more

Conditions: HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions: Mavacamten, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more

Conditions: Heart Disease, Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aortic Stenosis
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Female
Interventions: Control Arm ACSM Guidelines, Experimental Arm 6-12-25 repetitions per set; Other
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 20 Years to 89 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertrophic Scar
Interventions: Botox; Drug
Lead sponsor: Roy G. Geronemus, M.D.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Obstructive Sleep Apnea
Interventions: Tonsillectomy; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 17 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Left Ventricular Hypertrophy
Interventions: Exercise training, women, marathon; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

ELEVATE-HFpEF Clinical Study

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding

UTSW HP [13-C] Pyruvate Injection in HCM

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Large Language Models To Improve the Quality of Care of Cardiology Patients

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Stone and Laser Therapies Post-Market Study (SALT)

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Resistance Training and Blood Flow Restriction

Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure

Exercise in Genetic Cardiovascular Conditions

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Screening for Inherited Heart Disease

Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

Treatment of Hypertrophic Scars With Intradermal Botox

Tonsillectomy in Adults With Tonsillar Hypertrophy and Obstructive Sleep Apnea

Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism